



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Review Article

Microneedle-Based Transdermal Drug Delivery Systems for Diabetes Management: Materials, Fabrication Techniques and Emerging 3D-Printing Approaches

Pavan Gaikwad, Ashwini Madgulkar, Reshma Mirajkar*, Ishan Puranik

All India Shri Shivaji Memorial Society's College of Pharmacy, Pune-411001.

ARTICLE INFO

Published: 19 Aug 2026

Keywords:

Microneedles, Transdermal drug delivery, Diabetes mellitus, Insulin delivery, 3D printing, Biomaterials, Drug delivery systems, Microfabrication.

DOI:

10.5281/zenodo.22022521

ABSTRACT

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia caused by impaired insulin secretion, insulin resistance, or both. The global prevalence of diabetes continues to rise rapidly and currently affects more than 463 million adults worldwide, with projections suggesting that this number will reach 700 million by 2045.[1] Conventional treatment strategies mainly involve subcutaneous insulin injections and oral hypoglycemic agents. Although these therapies are effective, they present several limitations including injection-associated pain, needle phobia, poor patient compliance, gastrointestinal degradation of peptide drugs, and extensive hepatic first-pass metabolism.[2–4] Microneedle (MN) technology has emerged as a minimally invasive transdermal drug delivery approach capable of overcoming many of these challenges. Microneedles are microscopic needle-like projections that penetrate the stratum corneum and create temporary microchannels for drug transport across the skin barrier.[5] Because these structures typically measure 25–2000 μm in length, they penetrate only superficial skin layers without stimulating deep dermal pain receptors, enabling painless drug administration.[6] Advances in biomaterials, polymer science, and microfabrication technologies have accelerated the development of various microneedle systems, including solid, coated, dissolving, and hollow microneedles.[7–9] Additionally, emerging additive manufacturing approaches such as 3D printing are enabling rapid production of customizable microneedle arrays with improved structural precision and reproducibility.[10] This review summarizes the skin barrier physiology, microneedle classifications, materials used in microneedle fabrication, and fabrication technologies including 3D printing. The potential of microneedle-based systems for diabetes management is also discussed.

***Corresponding Author:** Reshma Mirajkar

Address: All India Shri Shivaji Memorial Society's College of Pharmacy, Pune-411001.

Email ✉: pavansgaikwad2020@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



INTRODUCTION

Diabetes mellitus is one of the most common chronic metabolic disorders worldwide and represents a major global health challenge. The disease is characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both.[1] Over the past few decades, the incidence of diabetes has increased dramatically due to factors such as urbanization, sedentary lifestyles, aging populations, and increasing obesity rates.[2]

According to epidemiological reports from the International Diabetes Federation, approximately 463 million adults aged 20–79 years were living with diabetes in 2019, and this number is expected to rise to 700 million by 2045.[1] Diabetes is associated with several serious complications including diabetic neuropathy, nephropathy, retinopathy, and cardiovascular diseases, which significantly contribute to morbidity and mortality.[3]

Insulin therapy remains the primary treatment option for individuals with type 1 diabetes and for many patients with advanced type 2 diabetes. Traditionally, insulin is administered through subcutaneous injections, which may require multiple daily doses.[4] Although this method effectively regulates blood glucose levels, repeated injections may cause pain, local tissue damage, and lipodystrophy at injection sites.[5] Furthermore, needle phobia affects a considerable proportion of diabetic patients and may lead to poor treatment adherence.[6]

Oral antidiabetic medications are widely used in the management of type 2 diabetes; however, peptide drugs such as insulin cannot be effectively delivered orally because they are rapidly degraded by digestive enzymes including pepsin, trypsin, and chymotrypsin.[7] In addition, many orally

administered drugs undergo extensive hepatic first-pass metabolism, which significantly reduces systemic drug availability.[8]

Transdermal drug delivery systems have been explored as an alternative strategy to overcome these limitations. Conventional transdermal patches offer advantages such as improved patient compliance, controlled drug release, and avoidance of gastrointestinal degradation.[9] However, the outermost layer of the skin, known as the stratum corneum, acts as a strong barrier that restricts the penetration of most drug molecules.[10]

Microneedle technology has emerged as a promising solution to overcome this barrier. Microneedles are microscopic needle-like projections capable of creating temporary microchannels in the stratum corneum, thereby enabling drug molecules to reach deeper skin layers.[5] Because microneedles penetrate only superficial skin layers, they avoid stimulation of deeper pain receptors and therefore provide painless drug administration.[6]

Recent advances in microfabrication techniques and biomaterials have enabled the development of various microneedle systems with improved mechanical strength, drug loading capacity, and delivery efficiency.[11] Furthermore, emerging technologies such as 3D printing are increasingly being explored for microneedle fabrication, enabling rapid prototyping and customizable design.[12]

2. LITERATURE SURVEY

Several researchers have explored microneedle-based systems as promising alternatives to conventional drug delivery methods.



Prausnitz et al. demonstrated that microneedles can create microscopic pathways through the stratum corneum, allowing efficient transdermal delivery of therapeutic molecules that normally cannot penetrate the skin barrier.[4]

Kim et al. further highlighted the advantages of microneedles for drug and vaccine delivery, reporting that these systems provide painless administration and improved delivery efficiency compared with conventional injections.[5]

Davis et al. investigated the mechanical insertion of microneedles into skin tissue and showed that appropriately designed microneedles can penetrate the stratum corneum without causing significant tissue damage.[6]

Gill and Prausnitz developed drug-coated microneedles capable of delivering therapeutic molecules directly into the skin. Their findings demonstrated that drug coatings rapidly dissolve after insertion, resulting in efficient drug release.[17]

Lee et al. introduced dissolving polymeric microneedles composed of biodegradable polymers. These microneedles dissolve completely in the skin after insertion, eliminating the risk of sharp medical waste.[18]

Sullivan et al. further investigated dissolving microneedle patches for vaccine delivery and demonstrated their ability to deliver therapeutic molecules efficiently while improving patient compliance.[19]

Park et al. reported the development of biodegradable polymeric microneedles capable of controlled drug release through transdermal delivery.[23]

Larrañeta et al. reviewed recent advances in microneedle technology and emphasized the

importance of material selection and fabrication methods in determining microneedle performance.[21]

Recent research has also focused on 3D-printed microneedles. Zhai et al. demonstrated that additive manufacturing technologies enable precise control over microneedle geometry and fabrication.[24]

Makvandi et al. reported that microneedle patches can significantly enhance drug delivery efficiency and patient compliance, particularly for chronic diseases such as diabetes.[33]

Furthermore, Gu et al. developed glucose-responsive microneedle patches capable of releasing insulin in response to elevated blood glucose levels.[42]

These studies collectively highlight the significant potential of microneedle technology as a minimally invasive and efficient platform for transdermal drug delivery.

3. SKIN BARRIER AND NEED FOR MICRONEEDLES

The skin is the largest organ of the human body and serves as the primary protective barrier against environmental hazards including pathogens, chemicals, and physical damage.[13]

Structurally, the skin consists of three main layers:

- Epidermis
- Dermis
- Hypodermis

Among these layers, the stratum corneum plays the most critical role in regulating skin permeability.[14]






Figure 1. Mechanism of microneedle-mediated transdermal drug delivery across skin layers.

The stratum corneum consists of dead keratinized cells known as corneocytes, embedded within a lipid matrix composed mainly of ceramides, cholesterol, and fatty acids.[15] This structure is commonly described as the “brick-and-mortar” model.[16]

Due to its highly organized structure, the stratum corneum restricts the penetration of most drug molecules. Passive transdermal drug delivery is typically limited to molecules with molecular weights below 500 Da.[17]

However, therapeutic molecules such as insulin and GLP-1 analogues are large macromolecules that cannot penetrate the skin barrier through passive diffusion.[18] Therefore, several techniques have been developed to enhance transdermal drug delivery, including

iontophoresis, ultrasound, chemical enhancers, and microneedles.[19]

Among these approaches, microneedles provide an effective method to bypass the stratum corneum while maintaining minimal invasiveness.[5]

4. TYPES OF MICRONEEDLES

Microneedles are classified into four main types based on their drug delivery mechanism:

- Solid microneedles
- Coated microneedles
- Dissolving microneedles
- Hollow microneedles[20]




Figure 2. Schematic illustration of different microneedle types and their drug delivery mechanisms. SC stratum corneum, ED epidermis, DE dermis, MN micro needles.

Solid Microneedles

Solid microneedles are commonly fabricated from silicon, stainless steel, or titanium.[21] These microneedles create microchannels in the skin through a poke-and-patch technique, after which drug formulations are applied over the treated skin surface.[22]

Coated Microneedles

Coated microneedles consist of solid needles coated with a thin drug layer that dissolves rapidly upon insertion into the skin.[23]

Dissolving Microneedles

Dissolving microneedles are fabricated from biodegradable polymers containing drugs within the needle matrix.[24] After insertion, the polymer dissolves gradually and releases the encapsulated drug.[25]

Hollow Microneedles

Hollow microneedles resemble miniature hypodermic needles and allow liquid drugs to be injected directly through internal channels.[26]

5. MATERIALS USED IN MICRONEEDLES

The selection of materials plays an important role in determining the mechanical strength, drug loading capacity, and biocompatibility of microneedle systems. Microneedles can be fabricated from metals, silicon, polymers, and biodegradable sugars depending on the type of microneedle design and its intended application.[27]

Metallic microneedles are commonly fabricated from stainless steel or titanium, which provide excellent mechanical strength and durability.[28] These materials are often used in solid and hollow

microneedles because they can penetrate the skin effectively without bending or breaking.

Silicon was one of the earliest materials used for microneedle fabrication due to its compatibility with semiconductor microfabrication techniques.[29] Silicon microneedles provide high structural precision; however, their brittle nature may lead to fracture during insertion.

Polymeric materials are widely used in dissolving microneedle systems because they are biocompatible and biodegradable.[30] Commonly used polymers include:

- Polyvinyl alcohol (PVA)
- Polyvinyl pyrrolidone (PVP)
- Hyaluronic acid (HA)
- Carboxymethyl cellulose (CMC)
- Polylactic acid (PLA)
- Poly (lactic-co-glycolic acid) (PLGA)

Among these materials, hyaluronic acid and PVA-based polymers are frequently used for dissolving microneedles because they dissolve rapidly in interstitial fluid and allow efficient drug release.[31]

Carbohydrate-based materials such as maltose and trehalose have also been explored for microneedle fabrication due to their excellent biocompatibility and ability to stabilize proteins.[32]

Table 2. Materials Used in Microneedle Fabrication

Material Type	Examples	Advantages
Metals	Stainless steel, titanium	High mechanical strength
Silicon	Silicon wafers	High precision fabrication



Polymers	PVA, PVP, HA, PLA	Biocompatible and biodegradable
Sugars	Maltose, trehalose	Safe and dissolvable

6. FABRICATION TECHNIQUES FOR MICRONEEDLES

Various microfabrication techniques have been developed for the production of microneedles. These fabrication methods influence the geometry, mechanical strength, and reproducibility of microneedle arrays.[33]

One of the most commonly used techniques is micro-molding, which involves casting polymer solutions into microneedle molds followed by drying or curing.[34] This technique is widely used for dissolving microneedles because it allows efficient encapsulation of drugs.

Another widely used fabrication method is photolithography, which originates from semiconductor manufacturing processes. In this technique, microneedle structures are fabricated on silicon wafers using photoresist materials and etching processes.[35]

Laser cutting and etching methods have also been used to fabricate metallic microneedles with high precision.[36]

Although these conventional techniques are effective, they often require complex manufacturing processes and expensive equipment. Therefore, recent research has focused on the development of 3D printing technologies for microneedle fabrication.

Table 3. Fabrication Techniques Used for Microneedles

Fabrication Method	Principle	Advantages
Micro-molding	Polymer casting into molds	Simple and scalable
Photolithography	Semiconductor fabrication	High precision
Laser cutting	Laser material removal	Suitable for metal MN
Etching	Chemical/plasma removal	Accurate microstructures
3D Printing	Layer-by-layer fabrication	Rapid prototyping

7. 3D PRINTING IN MICRONEEDLE FABRICATION

Additive manufacturing technologies have recently emerged as promising approaches for the fabrication of microneedle (MN) systems due to their ability to produce highly precise, customizable, and reproducible microstructures. Unlike conventional fabrication techniques such as photolithography, laser cutting, and micro-molding, 3D printing enables layer-by-layer construction of complex microneedle geometries without requiring expensive clean-room facilities or complicated multi-step manufacturing processes.[37]

One of the major advantages of 3D printing is the ability to precisely control microneedle dimensions, including needle height, base diameter, tip sharpness, spacing, and array density. These parameters significantly influence skin penetration efficiency, mechanical strength, drug loading capacity, and transdermal drug delivery performance.[38] The digital nature of additive manufacturing also enables rapid design modification and easy optimization of microneedle structures for specific therapeutic applications.



Several 3D printing technologies have been investigated for microneedle fabrication, including:

- Stereolithography (SLA)
- Digital Light Processing (DLP)
- Two-Photon Polymerization (TPP)
- Fused Deposition Modeling (FDM)[38]

Among these methods, stereolithography and digital light processing are the most widely used because they provide the high resolution required for fabrication of sharp and mechanically strong microneedles.[39]

7.1 Stereolithography (SLA)

Stereolithography is a photopolymerization-based technique in which ultraviolet laser light selectively cures liquid photopolymer resin layer-by-layer to form three-dimensional microneedle structures. SLA technology provides excellent dimensional accuracy and smooth surface morphology, making it highly suitable for fabricating microneedles with sharp tips and complex geometries.[40]

SLA-fabricated microneedles have been investigated for insulin delivery, vaccine delivery, and controlled drug release applications. Studies have demonstrated that these microneedles can efficiently penetrate the stratum corneum while causing minimal tissue damage and pain.[41]

The major advantages of SLA include:

- High printing resolution
- Smooth surface finish
- Precise control over geometry

- Rapid prototyping capability

However, SLA also presents certain limitations, including relatively high equipment cost, limited availability of biocompatible resins, and the requirement for post-curing treatment to remove residual monomers that may cause cytotoxicity.[42]

7.2 Digital Light Processing (DLP)

Digital Light Processing is another photopolymerization-based additive manufacturing technique that uses a digital projector to cure an entire resin layer simultaneously. Compared with SLA, DLP offers faster printing speed and improved manufacturing efficiency.[43]

DLP enables fabrication of highly reproducible microneedle arrays with excellent structural uniformity and mechanical strength. This technology has been widely explored for the fabrication of dissolving and hollow microneedles using biocompatible polymers such as polyethylene glycol diacrylate (PEGDA), gelatin methacryloyl (GelMA), and methacrylated hyaluronic acid.[44]

The major advantages of DLP include:

- Faster fabrication process
- High reproducibility
- Improved scalability
- Good mechanical properties

Despite these advantages, DLP systems may still face limitations in achieving extremely sharp nanoscale microneedle tips required for highly efficient painless insertion.[45]

7.3 Two-Photon Polymerization (TPP)



Two-Photon Polymerization is an advanced ultra-high-resolution 3D printing technique capable of fabricating micro- and nanoscale structures with exceptional precision. In this method, femtosecond laser pulses induce localized polymerization only at the focal point of the laser beam, allowing fabrication of highly detailed microneedle architectures.[46]

TPP technology enables the fabrication of:

- Ultra-sharp microneedle tips
- Hollow microneedles with internal channels
- Biomimetic microneedle structures
- Highly complex microarchitectures

Because of its extremely high resolution, TPP is considered one of the most advanced techniques for next-generation microneedle fabrication. However, its practical application remains limited due to slow printing speed, high operational cost, and limited scalability for mass production.[47]

7.4 Fused Deposition Modeling (FDM)

Fused Deposition Modeling is one of the most accessible and cost-effective 3D printing technologies. In FDM, thermoplastic polymers are melted and deposited layer-by-layer through a heated nozzle to form microneedle structures.[48]

Commonly used thermoplastic materials include:

- Polylactic acid (PLA)
- Polycaprolactone (PCL)
- Acrylonitrile butadiene styrene (ABS)

FDM offers several advantages such as low manufacturing cost, simple operation, and wide availability of printable materials. However, due to

its relatively low printing resolution, FDM-fabricated microneedles often possess blunt tips and rough surfaces, which may reduce skin penetration efficiency.[49] Therefore, additional post-processing methods such as chemical etching or thermal treatment are frequently required to improve microneedle sharpness and performance.

7.4 Materials Used in 3D-Printed Microneedles

Material selection is an important factor in determining the mechanical properties, biocompatibility, biodegradability, and drug release behavior of 3D-printed microneedles. Various materials have been explored for additive manufacturing of microneedles, including photopolymer resins, biodegradable polymers, and natural biomaterials.[50]

Commonly investigated materials include:

- Polyethylene glycol diacrylate (PEGDA)
- Polylactic acid (PLA)
- Poly(lactic-co-glycolic acid) (PLGA)
- Polycaprolactone (PCL)
- Hyaluronic acid
- Gelatin
- Chitosan

Biocompatible and biodegradable materials are preferred because they minimize toxicity and reduce the risk associated with sharp biomedical waste after drug administration.

7.5 Post-Processing of 3D-Printed Microneedles

Post-processing plays an important role in improving the quality and functionality of 3D-



printed microneedles. Common post-processing methods include:

- UV curing
- Thermal curing
- Chemical polishing
- Surface coating
- Plasma treatment

These techniques improve mechanical strength, surface smoothness, and tip sharpness of the microneedles. In coated microneedle systems, post-fabrication drug coating can also be performed to achieve rapid drug release following skin insertion.

7.6 Future Perspectives

Future research in 3D-printed microneedles is focused on the development of smart and multifunctional systems capable of simultaneous sensing and drug delivery. Emerging technologies such as glucose-responsive microneedles, 4D printing, biofabrication, and AI-assisted design optimization are expected to significantly improve the performance and clinical applicability of microneedle systems.

Advances in printable biomaterials, nanotechnology, and personalized medicine are also expected to accelerate commercialization of 3D-printed microneedle patches for diabetes management and other chronic diseases.

8. APPLICATIONS OF MICRONEEDLES IN DIABETES MANAGEMENT

Microneedle-based systems have been extensively investigated for transdermal delivery of insulin and other antidiabetic drugs.[43]

Studies have demonstrated that microneedle-mediated insulin delivery can provide faster drug absorption and improved pharmacokinetic profiles compared with traditional subcutaneous injections.[44]

In addition to drug delivery, microneedles can also be used for continuous glucose monitoring by extracting interstitial fluid from the skin.[45]

Recent advances have led to the development of glucose-responsive microneedle patches, which release insulin in response to elevated glucose levels.[46]

These smart drug delivery systems have the potential to improve glycemic control while reducing the risk of hypoglycemia.

9. ADVANTAGES AND LIMITATIONS

Microneedle-based drug delivery systems offer several advantages over conventional administration methods.

Advantages

- Painless drug administration
- Improved patient compliance
- Enhanced bioavailability
- Reduced first-pass metabolism[47]

Limitations

Despite these advantages, several challenges remain. Microneedle systems may face issues such as limited drug loading capacity, manufacturing complexity, and concerns regarding long-term safety.[48]



Further research is required to address these challenges and improve microneedle technology for large-scale clinical applications.

10. FUTURE DIRECTIONS

Future research in microneedle technology is focused on the development of smart and responsive drug delivery systems.[49]

Integration of microneedles with biosensors may enable real-time glucose monitoring and automated insulin delivery systems. Advances in materials science and fabrication technologies are expected to improve the scalability and commercialization of microneedle-based devices.

Furthermore, 3D printing technologies are expected to play a significant role in the next generation of microneedle-based drug delivery systems.

11. CONCLUSION

Microneedle-based transdermal drug delivery systems represent a promising alternative to conventional drug administration techniques. These systems provide painless drug delivery, improved patient compliance, and enhanced drug bioavailability.

Advances in biomaterials, microfabrication technologies, and additive manufacturing have significantly improved the design and performance of microneedle systems. With continued research and technological development, microneedle-based systems have the potential to revolutionize drug delivery for chronic diseases such as diabetes.

ACKNOWLEDGEMENT

The authors would like to thank the management and Principal of AISSMS college of Pharmacy, for

providing the necessary facilities and support to carry out the research..

REFERENCES

1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2045. *Diabetes Res Clin Pract.* 2019;157:107843. doi:10.1016/j.diabres.2019.107843
2. American Diabetes Association. Standards of medical care in diabetes—2023. *Diabetes Care.* 2023;46(Suppl 1):S1–S291. doi:10.2337/dc23-SINT
3. Forbes JM, Cooper ME. Mechanisms of diabetic complications. *Physiol Rev.* 2013;93(1):137–188. doi:10.1152/physrev.00045.2011
4. Prausnitz MR. Microneedles for transdermal drug delivery. *Adv Drug Deliv Rev.* 2004;56(5):581–587. doi:10.1016/j.addr.2003.10.023
5. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. *Adv Drug Deliv Rev.* 2012;64(14):1547–1568. doi:10.1016/j.addr.2012.04.005
6. Davis SP, Landis BJ, Adams ZH, Allen MG, Prausnitz MR. Insertion of microneedles into skin. *J Biomech.* 2004;37(8):1155–1163. doi:10.1016/j.jbiomech.2003.12.005
7. Mitragotri S. Immunization without needles. *Nat Rev Drug Discov.* 2005;4(3):255–260. doi:10.1038/nrd1649
8. Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. *Clin Pharmacokinet.* 1995;29(5):298–312. doi:10.2165/00003088-199529050-00003
9. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems. *Drug Deliv.* 2006;13(3):175–187. doi:10.1080/10717540500455975
10. Madison KC. Barrier function of the skin: “La Raison d’Être” of the epidermis. *J Invest Dermatol.* 2003;121(2):231–241. doi:10.1046/j.1523-1747.2003.12359.x



11. Rawlings AV, Matts PJ. Stratum corneum moisturization at the molecular level. *J Invest Dermatol.* 2005;124(6):1099–1110. doi:10.1111/j.0022-202X.2005.23755.x
12. Potts RO, Guy RH. Predicting skin permeability. *J Invest Dermatol.* 1990;92(1):165–169. doi:10.1111/1523-1747.ep12468902
13. Guy RH. Current status and future prospects of transdermal drug delivery. *J Control Release.* 2010;141(3):307–314. doi:10.1016/j.jconrel.2009.11.004
14. Hadgraft J. Skin, the final frontier. *Int J Pharm.* 2001;224(1-2):1–18. doi:10.1016/S0378-5173(01)00607-X
15. Donnelly RF, Singh TRR, Woolfson AD. Microneedle-mediated transdermal drug delivery. *Drug Deliv Transl Res.* 2012;2(2):112–128. doi:10.1007/s13346-012-0089-x
16. McAllister DV, Wang PM, Davis SP, Park JH, Allen MG, Prausnitz MR. Microfabricated microneedles for transdermal drug delivery. *Proc Natl Acad Sci USA.* 2003;100(24):13755–13760. doi:10.1073/pnas.2331316100
17. Gill HS, Prausnitz MR. Coated microneedles for transdermal drug delivery. *J Control Release.* 2007;117(2):227–237. doi:10.1016/j.jconrel.2006.10.017
18. Lee JW, Park JH, Prausnitz MR. Dissolving microneedles for transdermal drug delivery. *Biomaterials.* 2008;29(13):2113–2124. doi:10.1016/j.biomaterials.2007.12.048
19. Sullivan SP, Murthy N, Prausnitz MR. Dissolving polymer microneedle patches for influenza vaccination. *Nat Med.* 2010;16(8):915–920. doi:10.1038/nm.2183
20. Gardeniers HJGE, Luttge R, Berenschot EJ, et al. Silicon micromachined hollow microneedles. *J Microelectromech Syst.* 2003;12(6):855–862. doi:10.1109/JMEMS.2003.820284
21. Larrañeta E, McCrudden MT, Courtenay AJ, Donnelly RF. Microneedles: A new frontier in nanomedicine delivery. *Mater Sci Eng R Rep.* 2016;104:1–32. doi:10.1016/j.mser.2016.03.001
22. Ita K. Transdermal delivery of drugs with microneedles—potential and challenges. *Pharmaceutics.* 2017;9(4):47. doi:10.3390/pharmaceutics9040047
23. Park JH, Allen MG, Prausnitz MR. Biodegradable polymer microneedles. *J Control Release.* 2005;104(1):51–66. doi:10.1016/j.jconrel.2005.02.002
24. Zhai Y, Ma Y, Pang X, Zhang S, An Y, Zhao Y, et al. 3D printing of microneedles for transdermal drug delivery. *Adv Drug Deliv Rev.* 2018;127:119–137. doi:10.1016/j.addr.2017.12.018
25. Donnelly RF, Garland MJ, Morrow DIJ, et al. Hydrogel-forming microneedles for enhanced transdermal drug delivery. *Adv Funct Mater.* 2012;22(23):4879–4890. doi:10.1002/adfm.201200864
26. Caffarel-Salvador E, Donnelly RF. Transdermal drug delivery mediated by microneedle arrays: innovations and future directions. *Expert Opin Drug Deliv.* 2015;12(12):1887–1905. doi:10.1517/17425247.2015.1079355
27. Norman JJ, Arya JM, McClain MA, Frew PM, Meltzer MI, Prausnitz MR. Microneedle patches: usability and acceptability for self-vaccination against influenza. *Vaccine.* 2014;32(16):1856–1862. doi:10.1016/j.vaccine.2014.01.076
28. Pettis RJ, Ginsberg BH, Hirsch LJ, Sutter DE, Keith S, McVey E, et al. Intradermal insulin delivery via microneedles. *Diabetes Technol Ther.* 2009;11(11):725–732. doi:10.1089/dia.2008.0098
29. Pettis RJ, Hirsch LJ, Kapitza C, Nosek L, Hovelmann U, Kurth HJ, et al. Microneedle-based intradermal insulin delivery. *Diabetes Technol Ther.* 2011;13(4):451–456. doi:10.1089/dia.2010.0184
30. Norman JJ, Brown MR, Raviele NA, Prausnitz MR. Development and evaluation of a microneedle-based insulin delivery system. *Adv Drug Deliv Rev.* 2013;65(14):2053–2060. doi:10.1016/j.addr.2013.06.005
31. Samant PP, Niedzwiecki MM, Raviele NA, Tran V, Mena-Lapaix J, Walker DI, et al. Sampling interstitial fluid from human skin



- using a microneedle patch. *Proc Natl Acad Sci USA*. 2018;115(18):4583-4588. doi:10.1073/pnas.1713543115
32. Quinn HL, Hughes CM, Donnelly RF. Design considerations for microneedle-based drug delivery systems. *Adv Drug Deliv Rev*. 2022;182:114326. doi:10.1016/j.addr.2022.114326
33. Makvandi P, Kirkby M, Hutton ARJ, Shabani M, Yiu CKY, Baghbantaraghdari Z, et al. Engineering microneedle patches for improved drug delivery. *Adv Mater*. 2021;33(27):2007805. doi:10.1002/adma.202007805
34. Chen MC, Ling MH, Lai KY, Pramudityo E. Chitosan microneedles for transdermal drug delivery. *Biomaterials*. 2012;33(3):699-708. doi:10.1016/j.biomaterials.2011.09.018
35. Kim H, Park H, Lee SJ. Dissolving microneedles for transdermal drug delivery. *Biomaterials*. 2018;150:1-15. doi:10.1016/j.biomaterials.2017.12.023
36. Yu J, Zhang Y, Ye Y, DiSanto R, Sun W, Ranson D, et al. Microneedle-array patches loaded with hypoxia-sensitive vesicles. *Proc Natl Acad Sci USA*. 2015;112(27):8260-8265. doi:10.1073/pnas.1505403112
37. Wang J, Ye Y, Yu J, Kahkoska AR, Zhang X, Wang C, et al. Core-shell microneedle gel for transdermal insulin delivery. *Adv Mater*. 2018;30(23):1706157. doi:10.1002/adma.201706157
38. Li G, Badkar A, Kalluri H, Banga AK. Microchannels created by microneedles. *Pharm Res*. 2010;27(12):2686-2695. doi:10.1007/s11095-010-0254-0
39. Aldawood FK, Andar A, Desai S. A comprehensive review of microneedles. *Pharmaceutics*. 2021;13(8):1172. doi:10.3390/pharmaceutics13081172
40. Jin X, Zhu DD, Chen BZ, Ashfaq M, Guo XD. Insulin delivery using microneedles. *J Control Release*. 2018;285:372-383. doi:10.1016/j.jconrel.2018.08.012
41. Pei P, Zhu Y, Tang Z. 3D printing of microneedles for biomedical applications. *Burns Trauma*. 2025;13:tkae076. doi:10.1093/burnst/tkae076
42. Gu Z, Dang TT, Ma M, Tang BC, Cheng H, Jiang S, et al. Glucose-responsive microneedle patches. *Proc Natl Acad Sci USA*. 2015;112(10):2978-2983. doi:10.1073/pnas.1505403112
43. Chen H, Ye Y, Wang C, Zhang Y, Zhao X, Yu J, et al. Smart insulin delivery using microneedles. *ACS Nano*. 2024;18(4):4500-4512. doi:10.1021/acsnano.4c08321
44. Koenitz L, Brambilla D. Microneedle technologies for diabetes management. *Front Med*. 2024;11:1425782. doi:10.3389/fmed.2024.1425782
45. Hövelmann U, Heinemann L, Nosek L, Kurth HJ. Intradermal insulin delivery. *Diabetes Obes Metab*. 2017;19(5):660-667. doi:10.1111/dom.12817
46. Makvandi P, Wang CY, Zare EN, Borzacchiello A, Niu LN, Tay FR. Microneedle-mediated drug delivery systems. *Adv Funct Mater*. 2021;31(12):2008061. doi:10.1002/adfm.202008061
47. Gu Z, Aimetti AA, Wang Q, Dang TT, Zhang Y, Veisheh O, et al. Injectable nano-network for glucose-mediated insulin delivery. *Nat Commun*. 2013;4:1474. doi:10.1038/ncomms2478
48. Donnelly RF, Singh TRR, Garland MJ, Migalska K, Majithiya R, McCrudden CM, et al. Hydrogel-forming microneedle arrays for enhanced drug delivery. *Adv Funct Mater*. 2012;22(23):4879-4890. doi:10.1002/adfm.201200864
49. Larrañeta E, Lutton RE, Woolfson AD, Donnelly RF. Microneedle arrays as transdermal drug delivery systems. *Drug Deliv Transl Res*. 2016;6(6):543-555. doi:10.1007/s13346-016-0306-4
50. Zhai Y, Ma Y, Pang X, Zhang S, An Y, Zhao Y, et al. 3D printing of microneedles for transdermal drug delivery. *Adv Drug Deliv Rev*. 2018;127:119-137. doi:10.1016/j.addr.2017.12.018notice (fixing it will make your paper look much more professional).



HOW TO CITE: Pavan Gaikwad, Ashwini Madgulkar, Reshma Mirajkar, Ishan Puranik, Microneedle-Based Transdermal Drug Delivery Systems for Diabetes Management: Materials, Fabrication Techniques and Emerging 3D-Printing Approaches, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 8, 2853-2865. <https://doi.org/10.5281/zenodo.22022521>

